As sleep medicine enters a new therapeutic era, clinicians are facing a fundamental challenge: how can we determine which treatment is most appropriate for each patient with obstructive sleep apnea (OSA)?
At SLEEP 2026, Nox Medical will host a satellite symposium exploring how physiologic endotyping and AI-enabled analytics help transform OSA management from a one-size-fits-all approach to precision medicine.
Industry Product Theater
Endotyping Sleep Apnea: Precision Treatment in a Changing Therapeutic Landscape
Date: Tuesday, June 16, 2026
Time: 11:45 AM – 12:45 PM
Location: Hilton Baltimore, Holiday Ballroom 1–3
The symposium will bring together leading experts in sleep medicine, physiology, and translational research to discuss how endotyping is moving from the research laboratory into routine clinical practice.
The Next Frontier in Sleep Apnea Care
Sleep medicine is entering a new therapeutic era. As novel pharmacologic therapies and targeted treatment strategies emerge, the management of obstructive sleep apnea (OSA) is shifting beyond traditional device-based approaches toward more individualized care. This evolution raises a fundamental question: how can clinicians identify which therapy is most appropriate for each patient?
OSA endotyping provides a framework for addressing this challenge by characterizing the physiologic mechanisms that drive disease in individual patients, including airflow limitation, ventilatory control stability (loop gain), airway collapsibility, muscle compensation, and arousal threshold. These traits enable a transition from severity-based classification toward mechanism-based treatment selection.
Advances in artificial intelligence and signal processing are accelerating this shift. Novel approaches can now extract physiologic parameters from routine sleep studies, offering insights that extend beyond traditional metrics such as the apnea–hypopnea index. Platforms such as DeepResp MDaaS demonstrate how high-fidelity airflow data can be transformed into clinically meaningful metrics that support clinical decision support, refine risk assessment and guide targeted therapy alignment. These capabilities may support improved patient stratification, risk assessment, and treatment planning.
While further research and clinician guidance are needed to refine interpretation and predict individual treatment response, endotyping represents a promising tool for identifying patients most likely to benefit from specific therapies based on underlying pathophysiology. As new therapeutic options emerge and care models evolve, incorporating physiologic trait analysis into routine practice will be essential not only for precision treatment selection but also for resource optimization across increasingly complex sleep programs.
This symposium will explore how endotyping is evolving from a research concept to a practical tool in clinical sleep medicine. Expert speakers will discuss the physiologic foundations of OSA endotypes, the role of AI-enabled analytics in extracting meaningful signals from sleep data, and the implications of emerging therapies for precision treatment pathways. The session will also examine how clinicians and sleep programs can begin integrating physiologic trait analysis into routine practice as the therapeutic landscape continues to evolve.
A Distinguished Faculty of Experts
The symposium will feature presentations from internationally recognized leaders who have helped define the science of sleep apnea endotyping and precision sleep medicine.
Dr. Andrew Wellman: Understanding the Physiologic Origins of Endotypes
Dr. Andrew Wellman is Professor of Sleep Medicine at Harvard Medical School. His research focuses on the pathophysiology of Obstructive Sleep Apnea (OSA) and the development of methods to identify distinct endotypes of this disorder. By characterizing OSA endotypes, Dr. Wellman aims to create alternative treatments for the many patients who cannot tolerate continuous positive airway pressure (CPAP), including pharmacologic approaches.
Dr. Wellman will discuss the physiologic foundations of OSA endotypes and the mechanisms that contribute to disease expression in individual patients.
Dr. Danny Eckert: Why Endotypes Matter
Dr. Danny Eckert is a Matthew Flinders Professor at Flinders University, a National Health and Medical Research Council of Australia Leadership Fellow and a Lead Investigator at the Brigham and Women’s Hospital, Harvard Medical School, Boston (part-time). He serves as Director of the Flagship Sleep Health Program at Flinders University where he leads a comprehensive basic sciences and translational research program comprised of >120 multidisciplinary sleep researchers. Professor Eckert has published >250 papers in the leading sleep/respiratory and general medical journals. He is most well-known for his pioneering sleep apnoea mechanistic endo-phenotyping and treatment work which has led to new precision medicine approaches to treat this chronic respiratory condition including development of novel pharmacotherapy and for his broader sleep health research and advocacy work including leading the multi-award winning 3-part TV series, Australia’s Sleep Revolution with Dr Michael Mosley.
Dr. Eckert will explore how endotypes can support clinical decision-making and precision therapy.
Dr. Reena Mehra: Moving Toward Clinical Adoption
Dr. Reena Mehra is a clinician-scientist and epidemiologist whose work focuses on sleep disorders and their cardiopulmonary consequences through large NIH cohorts, clinical trials, and translational studies of sleep apnea pathophysiology and therapeutics. She is Division Head of Pulmonary, Critical Care and Sleep Medicine, tenured Professor of Medicine, and A. Bruce Montgomery, MD, American Lung Association Endowed Chair at the University of Washington. Nationally recognized in sleep and cardiovascular medicine, she has chaired major NIH and AHA initiatives, served as Associate Editor of the American Journal of Respiratory and Critical Care Medicine, authored the UpToDate chapter on obstructive sleep apnea and cardiovascular disease for over a decade, published more than 200 papers (>63,000 citations), delivered over 350 invited lectures internationally, and mentored more than 45 trainees.
Dr. Mehra will discuss where we are today and what is needed for widespread clinical adoption.
Nox Medical’s Role in Advancing Endotyping
The symposium will open with remarks from Emerson Kerr, VP of Market Development and Strategic Partnerships at Nox Medical, and include a presentation by Dr. Jón Ágústsson, VP of Artificial Intelligence and Data Research at Nox Medical on the evolution of endotyping at Nox Medical.
Emerson Kerr explained, “As the treatment landscape for obstructive sleep apnea continues to expand, clinicians need better tools to understand not just whether a patient has OSA, but why that patient’s OSA is occurring. Endotyping gives us a more physiologic view of disease, helping connect underlying traits such as airway collapsibility, ventilatory instability, arousal threshold, and muscle compensation to more individualized treatment pathways. At Nox Medical, we see AI-enabled endotyping as an important step toward making precision sleep medicine practical in everyday clinical care. By extracting deeper insights from routine sleep data, we can help clinicians move beyond one-size-fits-all decision-making and toward more targeted, evidence-informed care for each patient.”
Join Us at SLEEP 2026
As emerging therapies continue to reshape the treatment landscape for obstructive sleep apnea, understanding the physiologic mechanisms driving disease has never been more important.
Join Nox Medical and an exceptional panel of experts at SLEEP 2026 to explore how endotyping, AI-enabled analytics, and precision medicine are shaping the future of sleep apnea diagnosis and treatment.
We look forward to seeing you in Baltimore!
Add event to calendar:
Topic: Events
